Silexion Therapeutics (SLXN)
NASDAQ:SLXN
Total Valuation
Silexion Therapeutics has a market cap or net worth of $3.73M. The enterprise value is -$4.90M.
Market Cap$3.73M
Enterprise Value-$4.90M
Share Statistics
Silexion Therapeutics has 3,330,785 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,330,785
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Silexion Therapeutics’s return on equity (ROE) is -4.58 and return on invested capital (ROIC) is -250.74%.
Return on Equity (ROE)-4.58
Return on Assets (ROA)-1.65
Return on Invested Capital (ROIC)-250.74%
Return on Capital Employed (ROCE)-2.61
Revenue Per Employee0.00
Profits Per Employee-1.08M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Silexion Therapeutics is ―. Silexion Therapeutics’s PEG ratio is -0.00090.
PE Ratio―
PS Ratio0.00
PB Ratio0.98
Price to Fair Value0.98
Price to FCF-0.24
Price to Operating Cash Flow-0.32
PEG Ratio-0.00090
Income Statement
In the last 12 months, Silexion Therapeutics had revenue of 0.00 and earned -11.91M in profits. Earnings per share was -8.96.
Revenue0.00
Gross Profit-14.00K
Operating Income-11.63M
Pretax Income-11.91M
Net Income-11.91M
EBITDA-11.62M
Earnings Per Share (EPS)-8.96
Cash Flow
In the last 12 months, operating cash flow was -10.82M and capital expenditures -9.00K, giving a free cash flow of -10.83M billion.
Operating Cash Flow-10.82M
Free Cash Flow-10.83M
Free Cash Flow per Share-3.25
Dividends & Yields
Silexion Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change-90.94%
50-Day Moving Average1.57
200-Day Moving Average4.55
Relative Strength Index (RSI)33.87
Average Volume (3m)50.14K
Important Dates
Silexion Therapeutics upcoming earnings date is May 19, 2026, After Close (Confirmed).
Last Earnings DateMar 24, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Silexion Therapeutics as a current ratio of 2.41, with Debt / Equity ratio of 17.98%
Current Ratio2.41
Quick Ratio2.41
Debt to Market Cap0.18
Net Debt to EBITDA0.48
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Silexion Therapeutics has paid 3.00K in taxes.
Income Tax3.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Silexion Therapeutics EV to EBITDA ratio is 0.26, with an EV/FCF ratio of 0.27.
EV to Sales0.00
EV to EBITDA0.26
EV to Free Cash Flow0.27
EV to Operating Cash Flow0.27
Balance Sheet
Silexion Therapeutics has $5.99M in cash and marketable securities with $468.00K in debt, giving a net cash position of $5.52M billion.
Cash & Marketable Securities$5.99M
Total Debt$468.00K
Net Cash$5.52M
Net Cash Per Share$1.66
Tangible Book Value Per Share$1.96
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Silexion Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside183.02% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast91.47%